Hunter Associates Investment Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$914K Buy
15,806
+345
+2% +$19.8K 0.11% 153
2026
Q1
$936K Buy
15,461
+1,199
+8% +$69.9K 0.12% 144
2025
Q4
$767K Buy
14,262
+168
+1% +$8.08K 0.1% 150
2025
Q3
$639K Sell
14,094
-3,142
-18% -$147K 0.09% 165
2025
Q2
$800K Sell
17,236
-1,146
-6% -$56.3K 0.12% 148
2025
Q1
$1.12M Buy
18,382
+3
+0% +$175 0.17% 114
2024
Q4
$1.04M Buy
18,379
+504
+3% +$28.2K 0.16% 121
2024
Q3
$924K Sell
17,875
-436
-2% -$20.5K 0.14% 138
2024
Q2
$759K Sell
18,311
-51,857
-74% -$2.32M 0.13% 144
2024
Q1
$3.8M Buy
70,168
+4,807
+7% +$245K 0.64% 35
2023
Q4
$3.35M Sell
65,361
-868
-1% -$45.6K 0.61% 42
2023
Q3
$3.85M Buy
66,229
+4,176
+7% +$256K 0.78% 32
2023
Q2
$3.96M Buy
62,053
+3,408
+6% +$229K 0.77% 32
2023
Q1
$4.06M Buy
58,645
+5,914
+11% +$417K 0.87% 31
2022
Q4
$3.8M Sell
52,731
-6,884
-12% -$519K 0.92% 28
2022
Q3
$4.24M Sell
59,615
-78
-0.1% -$5.66K 1.1% 23
2022
Q2
$4.6M Buy
59,693
+17,897
+43% +$1.36M 1.14% 21
2022
Q1
$3.05M Buy
41,796
+9,089
+28% +$610K 0.98% 24
2021
Q4
$2.04M Buy
32,707
+6,000
+22% +$352K 0.58% 40
2021
Q3
$1.58M Sell
26,707
-12,000
-31% -$790K 0.51% 40
2021
Q2
$2.59M Sell
38,707
-15,635
-29% -$1.02M 0.81% 31
2021
Q1
$3.43M Buy
54,342
+834
+2% +$51.9K 0.79% 32
2020
Q4
$3.32M Sell
53,508
-1,214
-2% -$74.6K 0.82% 30
2020
Q3
$3.3M Buy
54,722
+1,284
+2% +$77.3K 0.92% 29
2020
Q2
$3.14M Sell
53,438
-1,402
-3% -$83.9K 0.93% 29
2020
Q1
$3.06M Buy
54,840
+431
+0.8% +$26.3K 1.18% 22
2019
Q4
$3.49M Buy
54,409
+35,901
+194% +$2.06M 1.08% 25
2019
Q3
$939K Buy
18,508
+115
+0.6% +$5.41K 0.32% 63
2019
Q2
$834K Hold
18,393
0.29% 72
2019
Q1
$878K Buy
18,393
+685
+4% +$34.1K 0.31% 69
2018
Q4
$920K Hold
17,708
0.37% 63
2018
Q3
$1.1M Hold
17,708
0.38% 64
2018
Q2
$980K Hold
17,708
0.35% 63
2018
Q1
$1.12M Sell
17,708
-780
-4% -$50.2K 0.42% 57
2017
Q4
$1.13M Buy
18,488
+780
+4% +$48.8K 0.42% 58
2017
Q3
$1.13M Sell
17,708
-250
-1% -$14.6K 0.44% 58
2017
Q2
$1M Sell
17,958
-333
-2% -$18.1K 0.41% 56
2017
Q1
$995K Sell
18,291
-360
-2% -$19.7K 0.42% 57
2016
Q4
$1.09M Hold
18,651
0.47% 53
2016
Q3
$1.01M Buy
18,651
+200
+1% +$12.8K 0.43% 56
2016
Q2
$1.36M Sell
18,451
-1,000
-5% -$70.7K 0.59% 48
2016
Q1
$1.24M Hold
19,451
0.57% 50
2015
Q4
$1.34M Hold
19,451
0.59% 47
2015
Q3
$1.15M Hold
19,451
0.54% 48
2015
Q2
$1.29M Hold
19,451
0.54% 49
2015
Q1
$1.25M Sell
19,451
-3,200
-14% -$200K 0.49% 50
2014
Q4
$1.34M Sell
22,651
-600
-3% -$33.8K 0.51% 49
2014
Q3
$1.19M Sell
23,251
-1,266
-5% -$63.2K 0.46% 56
2014
Q2
$1.19M Sell
24,517
-3,491
-12% -$172K 0.47% 56
2014
Q1
$1.46M Sell
28,008
-13,800
-33% -$734K 0.57% 40
2013
Q4
$2.22M Sell
41,808
-2,561
-6% -$130K 0.86% 34
2013
Q3
$2.05M Sell
44,369
-1,530
-3% -$67.2K 0.86% 34
2013
Q2
$2.05M Buy
+45,899
New +$1.99M 0.76% 33

Other funds holding BMY

Hunter Associates Investment Management's BMY Position: Q2 2026 in Review

Hunter Associates Investment Management increased its Bristol-Myers Squibb (BMY) stake by 2.2% in Q2 2026, buying an estimated $19.8K and bringing the position to 15,806 shares worth $914K. The position accounts for 0.11% of the portfolio, ranked #153.

Hunter Associates Investment Management first reported a position in BMY in Q2 2013 and has held it in 53 quarters since. The position peaked at $4.6M in Q2 2022. 954 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Hunter Associates Investment Management held 15,806 shares of Bristol-Myers Squibb worth $914K as of Q2 2026.
  • Hunter Associates Investment Management bought 345 Bristol-Myers Squibb shares in Q2 2026, an estimated $19.8K.
  • Bristol-Myers Squibb made up 0.11% of Hunter Associates Investment Management's portfolio in Q2 2026, its #153 holding.
  • Hunter Associates Investment Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 53 quarters since.
  • Hunter Associates Investment Management's Bristol-Myers Squibb position peaked at $4.6M in Q2 2022.
  • 954 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Hunter Associates Investment Management's 13F filing for Q2 2026, filed 23 Jul 2026.